Real-World Outcomes of Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction
Global Cardiology Science and Practice · 22.05.2026 · 2026 (S2)
DOI: 10.21542/gcsp.2026.s2.78 ↗Kurz gefasst
Fachartikel in der Zeitschrift Global Cardiology Science and Practice, online erschienen am 22.05.2026. Verfasst von Rashed Al-Marmouri. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background
Sacubitril/valsartan, an angiotensin receptor–neprilysin inhibitor (ARNI), is a foundational therapy for heart failure with reduced ejection fraction (HFrEF), proven in randomized trials to reduce mortality and hospitalizations. However, translating these results into real-world clinical practice requires evaluation in broader, less selected patient populations. This study assessed the real-world effectiveness and safety of sacubitril/valsartan in patients with HFrEF, focusing on mortality, rehospitalization, functional improvement, and tolerability.
Methods
We conducted a retrospective cohort analysis of approximately 5,400 patients with HFrEF initiated on sacubitril/valsartan between 2016 and 2023. Data were collected from linked electronic health records and national registries, including baseline demographics, NYHA functional class, and laboratory parameters. The primary endpoints were all-cause mortality and heart failure–related hospitalizations, while secondary outcomes included changes in NYHA class and treatment-emergent adverse events such as renal dysfunction, hyperkalemia, and hypotension. Each patient’s outcomes after ARNI initiation were compared with their pre-treatment period, with subgroup analyses performed in older adults (≥75 years) and those with advanced functional limitation (NYHA III/IV).
Results
Over a mean follow-up of more than five years, initiation of sacubitril/valsartan was associated with significant clinical improvement. NYHA functional class improved markedly from baseline (p
Zitieren
APA
Al-Marmouri, R. (2026). Real-World Outcomes of Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction. Global Cardiology Science and Practice, 2026(S2). https://doi.org/10.21542/gcsp.2026.s2.78
Vancouver
Al-Marmouri R. Real-World Outcomes of Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction. Global Cardiology Science and Practice. 2026;2026(S2). doi:10.21542/gcsp.2026.s2.78
BibTeX
@article{AlMarmouri2026,
author = {Al-Marmouri, Rashed},
title = {Real-World Outcomes of Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction},
journal = {Global Cardiology Science and Practice},
year = {2026},
volume = {2026},
number = {S2},
doi = {10.21542/gcsp.2026.s2.78}
}
EUVIMED